YWYu-Mei Wang

Yu-Mei Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yu-Mei Wang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Lina Zhou

    Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Qian Zhong

    Department of Gynecology and Obstetrics, Second West China Hospital, and State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China

    1 shared publication
  • Shengtao Zhou

    Department of Obstetrics and Gynecology, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University, and Collaborative Innovation Center, Chengdu, PR China; Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, West China Second University Hospital, Sichuan University, Chengdu, PR China

    1 shared publication
  • Tao Yi

    Department of Gynecology and Obstetrics, Key Laboratory of Birth Defects and Related Diseases of Women and Children of The Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China

    1 shared publication
  • Xia Zhao

    Department of Gynecology and Obstetrics, Key Laboratory of Obstetric and Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second Hospital; State Key Laboratory of Biotherapy and Cancer Center, Sichuan University, Chengdu 610041, Sichuan, P.R. China

    1 shared publication
  • Xian-Ping Liu

    Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, China

    1 shared publication

Latest Publications

  • Open Access

    Anti-tumor activity of N-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model

    by Xian-Ping Liu, Sheng-Tao Zhou, Xing-Yi Li, Xian-Cheng Chen, Xia Zhao, Zhi-Yong Qian, Li-Na Zhou, Zhi-Yong Li, Yu-Mei Wang, Qian Zhong, et al.

    Background: Camptothecin (CPT) has recently attracted increasing attention as a promising anticancer agent for a variety of tumors. But the clinical application is largely hampered by its extreme water insolubility and unpredictable side effect. It is essential to establish an efficient and safe protocol for the administration of CPT versus melanoma. Methods: Camptothecin was encapsulated with N-trimethyl chitosan (CPT-TMC) through microprecipitation and sonication. Its inhibition effect on B16-F10 cell proliferation and induction of apoptosis was evaluated by MTT assay and flow cytometric analysis in vitro. The anti-tumor activity of CPT-TMC was evaluated in C57BL/6 mice bearing B16-F10 melanoma. Tumor volume, tumor weight and survival time were recorded. Assessment of apoptotic cells within tumor tissue was performed by TUNEL assay. Antiangiogenesis and antiproliferation effects of CPT-TMC in vivo were conducted via CD31 and PCNA immunohistochemistry, respectively. Results: CPT-TMC efficiently inhibited B16-F10 cells proliferation and increased apoptosis in vitro. Experiment group showed significant inhibition compared with free CPT-treated group (81.3% vs. 56.9%) in the growth of B16-F10 melanoma xenografts and prolonged the survival time of the treated mice (P < 0.05). Decreased cell proliferation, increased tumor apoptosis as well as a reduction in angiogenesis were observed. Conclusions: Our data suggest that N-trimethyl chitosan-encapsulated camptothecin is superior to free CPT by overcoming its insolubility and finally raises the potential of its application in melanoma therapy.